Abstract: Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.

Abstract: A method for making a reference leak includes the steps of: (a) preparing a substrate; (b) forming a patterned catalyst layer on the substrate, the patterned catalyst layer comprising one or more catalyst blocks; (c) forming one or more elongate nano-structures extending from the corresponding catalyst blocks by a chemical vapor deposition method; (d) forming a leak layer of one of a metallic material, a glass material, and a ceramic material on the substrate with the one or more elongate nano-structures partly or completely embedded therein; and (e) removing the one or more elongate nano-structures and the substrate to obtain a reference leak with one or more leak holes defined therein.

Abstract: Novel, monodispersed, spherical ZrO2 particles in the size range of approximately 10 to approximately 600 nm exhibiting metastable tetragonal crystal structure at room temperature and novel methods of preparation. The ZrO2 particles are approximately 100% in the tetragonal phase at room temperature and can be pure and free of foreign oxides. The novel method can include mixing zirconium-alkoxide and an alcohol, forming preparation one, followed by separately dissolving completely de-ionized water and a polymeric steric stabilizer in an alcohol forming preparation two. Next the preparations can be mixed with vigorous stirring while subjecting the materials to hydrolysis and condensation reactions with very slow stirring. Next, there is waiting for the formation of a sol from the mixture, followed by drying at approximately 80 degrees C. to form resultant material followed by crushing the resultant material.

Abstract: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.

Abstract: The present invention relates to a magnetic impedance measurement device comprising an apply coil for generating an alternate magnetic field of variable frequency, a power source for the apply coil, at least one magnetic sensor means comprising a pair of magnetic sensors for detecting orthogonal vector components of a magnetic field generated from a test object, the vector components being parallel to the face of the apply coil, a measurement means for the magnetic sensor for measuring a detected signal from said magnetic sensor mean, the measurement means being located at a distance from the face of the apply coil and facing the test object, a lock-in amplifier circuit for detecting from an output of the measurement means a signal having the same frequency as the frequency of the apply coil and an analysis means for analyzing intensity and phase changes of an output of the magnetic sensor means with the use of an output signal of the lock-in amplifier circuit.

Abstract: Methods and compositions to prevent scarring of the skin include a matrix metalloproteinase inhibitor and a vehicle suitable for topical application. Scarring and damage to the epidermis and extracellular matrix may be reduced and/or prevented. Following skin damage, application of the matrix metalloproteinase inhibitor reduces expansion of the extracellular matrix portion of the skin compared to untreated skin.

Abstract: A method for measuring an upper limb reaching capability of a user with an impaired limb is provided. Each upper limb is placed at a default position on a horizontal surface. A target is displayed from among a plurality of targets on the horizontal surface. One of the limbs reaches for the target. Limb choice, position information and elapsed time are sensed and recorded. The reaching limb is retracted to the default position. The displaying step through the retracting step are repeated for each of the plurality of targets, wherein each of the plurality of targets is spaced apart.

Abstract: First, an object model library and an operation module library are provided. The object model library contains at least an object model geometrically similar to a real object to be processed. The operation module library contains at least an operation module for each operation to be performed. Then, for each real object to be processed, a virtual object is defined by association with an object model in the object model library and by specification of the object model's geometric parameters. Subsequently, for each operation to be performed, the operation is defined by selecting an operation module from the operation module library and specifying its operation parameters. Optionally, for each virtual object defined, at least a two-dimensional image previously taken of the corresponding real object is associated with the virtual object.

Abstract: A method for separating fractions of single-walled carbon nanotubes includes exposing a solution containing fractions of single-walled carbon nanotubes to a reducing agent and separating the resulting reaction products. An alternate method for separating fractions of single-walled carbon nanotubes includes exposing a solution containing fractions of single-walled carbon nanotubes to an oxidizing agent and separating the resulting reaction products. A third method for separating fractions of single-walled carbon nanotubes includes exposing a solution containing fractions of substantially non-functionalized single-walled carbon nanotubes to a charge transfer complex agent and separating the resulting reaction products. These methods allow the production of single-walled carbon nanotubes of approximately 95 to 99% metallic and semiconducting types.

Abstract: The invention is in general directed to compounds and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, methods of screening for compounds useful in preventing or alleviating the symptoms of amyloid-associated diseases, methods of diagnostic imaging of A-beta fibrils, and compounds and methods useful for studying normal or disease-associated cellular mechanisms relating to amyloid proteins.

Abstract: Screening assays and methods of employing the screening assays designed to identify potential inhibitors of amyloidal neurodegenerative disease. The screening assays comprises providing a membrane construct disposed on a substrate and contacting the membrane construct with A? peptide capable of forming an A? peptide ion channel in the construct. The membrane construct is then contacted with a test compound. A? peptide ion channel activity is determined after the construct has incubated with the A? peptide in the presence and in the absence of the test compound. A reduction in the A? peptide ion channel activity of the membrane construct contacted with the test compound in comparison to a different membrane construct contacted with the same A? peptide in the absence of said test compound indicates that the test compound is an inhibitor of amyloidal neurodegenerative disease.

Abstract: A system and method of identifying relational patterns across a plurality of databases using a data structure and the data structure itself. The data structure including one or more data node branches, each of the one or more data node branches including one or more data nodes, each of the one or more data nodes representing a data item of interest and corresponding data item support values for the data item across the plurality of databases in relation to other data items represented in the data node branch. The data structure can be used to mine one or more relational patterns considering pattern support data across the plurality of databases at the same time.

Abstract: A method for detecting coupled RF current magnetic resonance (MR) objects in a body and determining MR risk is provided. The body is scanned with reverse circularly polarized RF. MR signals generated by coupling of the reverse circularly polarized RF with the RF current MR objects are detected. The detected MR signals are used to determine a risk value.

Abstract: An elastomeric polymer, comprising (1) a hard segment in the amount of 10% to 60% by weight of the elastomeric polymer, wherein the hard segment includes a urethane, urea or urethaneurea; and (2) a soft segment in the amount of 40% to 90% by weight of the elastomeric polymer. The soft segment comprises (a) at least 2% by weight of the soft segment of at least one polyether macrodiol, and/or at least one polycarbonate macrodiol; and (b) at least 2% by weight of the soft segment of at least one polyisobutylene macrodiol and/or diamine.

Abstract: A method of forming a device with a piezoresistor is disclosed herein. In one embodiment, the method includes providing a substrate, etching a trench in the substrate to form a vertical wall, growing a piezoresistor layer epitaxially on the vertical wall, and separating the vertical wall from an underlying layer of the substrate that extends along a horizontal plane such that the piezoresistor layer is movable with respect to the underlying layer within the horizontal plane.

Abstract: The present invention includes methods of making and methods of using peptidomimetics compositions that mimic ?-helical BH3 sequences in cells. The peptidomimetics can be used to mimic ?-helical BH3 sequences and kill cancer cells.

Abstract: Methods and devices of stimulating nerves are disclosed. In one embodiment adapted for stimulating excitable tissue, the invention includes drive circuitry (12), an acoustic transducer (14) and a pair of electrodes (28).

Abstract: An apparatus for treating the brain, comprises a first fluid delivery device including a distal end sized and shaped for placement at a first target site between a dura mater and a pia mater of the brain, the first fluid delivery device including a first fluid lumen extending to a first outlet port in the distal end to deliver fluids to a first target location and a first microelectrode mounted within the distal end of the first fluid delivery device for movement between an insertion position in which a first distal tip of the first microelectrode is received within the first fluid delivery device and a deployed position in which the first microelectrode extends out of the first fluid delivery device with the first distal tip thereof penetrating the pia mater to a first electrode target position in the cerebral cortex.

Abstract: Methods to use beta glucans in the culture of cell populations containing CD34+ cells in order to expand the numbers of CD34+ subsets of progenitor and stem cells are provided. Methods to improve homing and engraftment of stem and progenitor cells by first culturing the cells with beta glucans, or co-administering with beta glucans, are also provided. Additionally, methods to ameliorate chemotherapy toxicity and promote development of functionally active neutrophils by administering beta glucans are presented. The beta glucans are preferably extracted from maitake mushroom (Grifola frondosa).

Abstract: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are useful to modulate (e.g. agonize or antagonize) opioid receptor function.